Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
Thumbnail

Risk score predicts new‐onset HF among AFib patients in the ED

The study's authors hope their work can help high-risk patients receive the care they need. 

Thumbnail

Dapagliflozin significantly improves HFpEF symptoms

One researcher described the findings, presented at the Heart Failure Society of America's Annual Scientific Meeting, as "great news for patients and clinicians."

Specialists explore relationship between COVID-19 and heart failure, highlighting importance of vaccination

"The rise of the delta variant of COVID-19 is a reminder that this pandemic is not over," the president of the Heart Failure Society of America said in a statement. 

Thumbnail

Making progress: Heart tissue developed in a laboratory shows promise

These findings, one specialist said, could provide a significant piece to "the puzzle of heart development."

Risk of heart damage higher after COVID-19 than vaccination

The new analysis, published in the New England Journal of Medicine, included data from more than 2.1 million patients.

Thumbnail

FDA-approved antiplatelet medication may be an effective heart failure treatment

Additional research is still needed, but researchers may have uncovered a new treatment for heart failure.

Thumbnail

LVAD therapy benefits older heart failure patients—but remains underutilized

The new analysis, which included data from more than 24,000 adult patients, was published in the Journal of the American College of Cardiology. 

Empagliflozin gains FDA approval as treatment for adult HFrEF patients

The FDA’s decision was based largely on results from a clinical trial that included more than 3,700 heart failure patients with a left ventricular ejection fraction of 40% or less.

Displaying 337 - 344 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.